Home » Newsletters » BioWorld Science

BioWorld Science

March 18, 2003

View Archived Issues

Bayer researchers describe novel series of selective factor Xa inhibitors

New alpha2beta1 integrin antagonists identified at Ajinomoto

Novel inhibitors of DNA polymerase IIIC with potential as antibacterial agents

BioMarin achieves positive phase II results for Aryplase

Pozen's NDA for MT-300 accepted for filing by FDA

Hemosol to review safety data prior to continuing cardiac trial

Prana expands collaboration with U. of Melbourne

Three related series of antitumor tyrosine kinase inhibitors patented by Merck

New HIV RT inhibitors identified by Boehringer Ingelheim researchers

Novel histamine H3 antagonists for use in obesity and diabetes

Pharmacia patent covers 5-HT6 receptor ligands and their use

Aventis scientists prepare and test new tubulin polymerization inhibitors

Novel PPAR agonists discovered by Merck researchers

Antipsychotic GlyT-1 inhibitors in early development at Pfizer

Millennium claims new heterocyclic 5-LO inhibitors

New data on the efficacy of omalizumab in allergic rhinitis and asthma

(PE)HRG214 reported well tolerated in HIV-infected patients

Efficacy and safety of intravesical resiniferatoxin in detrusor instability and hyperreflexia

Potential of TAC-101 in human testicular cancer

Discovery of new compounds for diabetes and obesity accelerated at Yamanouchi

WX-G250 + low-dose IL-2 safe and active in progressive, metastatic RCC

BG00001 may not cause sterility in prostate cancer patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...